Ertugliflozin

(Steglatro)

Ertugliflozin

Drug updated on 11/14/2023

Dosage FormTablet (oral: 5 mg, 15 mg)
Drug ClassSodium glucose co-transporter 2 (SGLT2) inhibitors
Ongoing and Completed StudiesClinicalTrials.gov

Indication

  • Indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.

Product Monograph / Prescribing Information

Document TitleYearSource
Steglatro (ertugliflozin) Prescribing Information. 2022Merck & Co., Inc., Rahway, NJ

Systematic Reviews / Meta-Analyses

Document TitleYearSource
Effect of ertugliflozin on renal function and cardiovascular outcomes in patients with type 2 diabetes mellitus: A systematic review and meta-analysis.2023Medicine
A model-based meta analysis study of sodium glucose co-transporter-2 inhibitors.2023CPT: Pharmacometrics & Systems Pharmacology
Efficacy and safety of ertugliflozin in type 2 diabetes: a systematic review and meta-analysis. 2022Frontiers in Pharmacology
Association of SGLT2 inhibitors with risk of atrial fibrillation and stroke in patients with and without type 2 diabetes: a systemic review and meta-analysis of randomized controlled trials.2022Journal of Cardiovascular Pharmacology
Renal protective effect and safety of sodium-glucose cotransporter-2 inhibitors in patients with chronic kidney disease and type 2 diabetes mellitus: a network meta-analysis and systematic review.2022International Urology and Nephrology
Comparative efficacy of glucose-lowering medications on body weight and blood pressure in patients with type 2 diabetes: a systematic review and network meta-analysis. 2021Diabetes, Obesity and Metabolism
Effect of sodium-dependent glucose transporter inhibitors on glycated hemoglobin A1c after 24 weeks in patients with diabetes mellitus: a systematic review and meta-analysis. 2021Medicine
Safety and efficacy of SGLT2 inhibitors: a multiple-treatment meta-analysis of clinical decision indicators.2021Journal of Clinical Medicine
Comparative efficacy of dual and single initiation of add-on oral antihyperglycemic agents in type 2 diabetes uncontrolled on metformin alone: a systematic literature review and network meta-analysis.2021Diabetes Therapy
Comparison of new oral hypoglycemic agents on risk of urinary tract and genital infections in type 2 diabetes: a network meta-analysis. 2021Advances in Therapy
Meta-analysis of noncompartmental pharmacokinetic parameters of ertugliflozin to evaluate dose proportionality and UGT1A9 polymorphism effect on exposure. 2021Pharmacogenomics
Effectiveness and safety of ertugliflozin for type‚ÄČ2 diabetes: a meta-analysis of data from randomized controlled trials.2021Journal of Diabetes Investigation
Assessment report: Stelglatro.2021EMA
The effects of sodium glucose co-transporter (SGLT) 2 inhibitors on hematocrit levels: a systematic review and meta-analysis of randomized controlled trials.2021Annals of Palliative Medicine
Effect of ertugliflozin on glycemic levels, blood pressure and body weight of patients with type 2 diabetes mellitus: a systematic review and meta-analysis.2020Journal of Diabetes & Metabolic Disorders
Ertugliflozin as monotherapy or with metformin for treating type 2 diabetes. 2019NICE
Clinical review report: ertugliflozin (Steglatro). 2019CADTH

Clinical Practice Guidelines

Document TitleYearSource
Pharmacologic glycemic management of type 2 diabetes in adults. 2018Canadian Journal of Diabetes